2. Search Result
Search Result
Results for "

Acromegaly

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

7

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3124A
    BIM-23190 hydrochloride

    		Somatostatin Receptor Cancer
    BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    BIM-23190 hydrochloride
  • HY-P0036
    Octreotide
    Maximum Cited Publications
    8 Publications Verification

    SMS 201-995

    		 Somatostatin Receptor Apoptosis Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide
  • HY-P0036B
    Octreotide pamoate

    SMS 201-995 pamoate

    		 Somatostatin Receptor Apoptosis Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly .
    Octreotide pamoate
  • HY-P3124
    BIM-23190

    		Somatostatin Receptor Cancer
    BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .
    BIM-23190
  • HY-153485A
    Cimdelirsen sodium

    ISIS 766720 sodium; IONIS-GHR-LRx sodium

    		 Small Interfering RNA (siRNA) Others
    Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
    Cimdelirsen sodium
  • HY-153485
    Cimdelirsen

    ISIS 766720; IONIS-GHR-LRx

    		 Small Interfering RNA (siRNA) Others
    Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.
    Cimdelirsen
  • HY-109155
    Paltusotine
    1 Publications Verification

    CRN00808

    		 Somatostatin Receptor Endocrinology Cancer
    Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors .
    Paltusotine
  • HY-16381
    Pasireotide

    SOM230

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide
  • HY-16381A
    Pasireotide acetate
    1 Publications Verification

    SOM230 acetate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide acetate
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: